Actively Recruiting
Randomized Study of ALTO-100 Versus Placebo in Adults With Bipolar Disorder and Major Depression Followed by Open-Label Treatment
Led by Alto Neuroscience · Updated on 2026-10-13
200
Participants Needed
68
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.
CONDITIONS
Brief Title
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Research Team
A
Alto Neuroscience
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here